# LymphoPilot First-in-Human Trial of Implantable Lymphatic Device Shows Safety and Efficacy in Breast Cancer Lymphedema

> clinical trial · REPORTED · 2025-02-12

A peer-reviewed publication in the European Journal of Internal Medicine reported that the LymphoPilot first-in-human trial of Lymphatica Medtech's LymphoDrain implant in nine breast cancer-related lymphedema patients demonstrated no safety concerns and significant reductions in limb volume without requiring manual lymphatic drainage or compression therapy over an eight-week implantation period. The device uses subcutaneous catheters and a micropump system to actively manage lymphatic fluid.

About Lymphatica Medtech: Lymphatica Medtech is a Swiss medical device company developing LymphoDrain, a first-of-its-kind permanent implantable micropump device designed to replicate lymphatic vessel function and actively drain interstitial fluid in patients with secondary lymphedema, particularly breast cancer-related lymphedema.

- Company: Lymphatica Medtech
- Sector: medical devices
- Primary source: https://www.ejinme.com/article/S0953-6205(25)00037-8/fulltext

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.